Добірка наукової літератури з теми "Eribulin Mesylate"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Eribulin Mesylate".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Eribulin Mesylate"
Huyck, Timothy K., William Gradishar, Fil Manuguid, and Peter Kirkpatrick. "Eribulin mesylate." Nature Reviews Drug Discovery 10, no. 3 (March 2011): 173–74. http://dx.doi.org/10.1038/nrd3389.
Повний текст джерелаJain, Sarika, and Linda T. Vahdat. "Eribulin Mesylate." Clinical Cancer Research 17, no. 21 (August 22, 2011): 6615–22. http://dx.doi.org/10.1158/1078-0432.ccr-11-1807.
Повний текст джерелаEdwards, Michael S., Dominic A. Solimando, and J. Aubrey Waddell. "Eribulin Mesylate and Denosumab." Hospital Pharmacy 46, no. 4 (April 2011): 247–53. http://dx.doi.org/10.1310/hpj4604-247.
Повний текст джерелаVerdaguer, Helena, Idoia Morilla, and Ander Urruticoechea. "Eribulin Mesylate in Breast Cancer." Women's Health 9, no. 6 (November 2013): 517–26. http://dx.doi.org/10.2217/whe.13.61.
Повний текст джерелаNieder, Carsten, Gro Aandahl, and Astrid Dalhaug. "A Case of Brain Metastases from Breast Cancer Treated with Whole-Brain Radiotherapy and Eribulin Mesylate." Case Reports in Oncological Medicine 2012 (2012): 1–3. http://dx.doi.org/10.1155/2012/537183.
Повний текст джерелаBarnato, Sara E., Jacqueline Sara Jeruss, Kevin P. Bethke, Nora M. Hansen, Seema Ahsan Khan, Jamie H. Von Roenn, Steven T. Rosen, et al. "Phase II neoadjuvant trial with carboplatin and eribulin mesylate in patients with triple-negative breast cancer." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): TPS1134. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.tps1134.
Повний текст джерелаPullela, Srinivas Venkata, Vinod Acharya, Nagarjuna Reddy, Jayvant Harlikar, Amar Kulkarni, Rakesh Chavan, Ajay Yadav, Shuvendu Manna, and Angshuman Ghosh. "Structural corroboration of two important building blocks of the anticancer drug eribulin mesylate through two-dimensional NMR and single-crystal X-ray diffraction studies." Acta Crystallographica Section C Structural Chemistry 72, no. 1 (January 1, 2016): 14–20. http://dx.doi.org/10.1107/s2053229615022305.
Повний текст джерелаNasim, Muhammad Yaser, Ruth Plummer, T. R. Jeffry Evans, Rosemary Morrison, David Alan Anthoney, Sophie Haney, Ayman Madi, et al. "A phase Ib dose-escalation study of eribulin mesylate in combination with capecitabine in patients with advanced/metastatic cancer." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 2552. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.2552.
Повний текст джерелаIwamoto, Mitsuhiko, Nayuko Sato, Risa Terasawa, Hiroya Fujioka, Yuko Takahashi, Kosei Kimura, Satoru Tanaka, and Kazuhisa Uchiyama. "Phase II study of eribulin mesylate as first- or second-line therapy for metastatic HER2-negative breast cancer." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): TPS1140. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.tps1140.
Повний текст джерелаRaftopoulos, Harry, Joseph Aisner, Kirushna Kumar, Sanjay Goel, Christian Dittrich, Minish Jain, Prashanth Gopalakrishna, Paloma Salazar, Beverley Jones, and Daniel Peter Petrylak. "Phase Ib extension study of eribulin mesylate in combination with carboplatin in patients with chemotherapy-naive advanced non-small cell lung cancer (NSCLC)." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): e19145-e19145. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e19145.
Повний текст джерелаЧастини книг з теми "Eribulin Mesylate"
Bauer, Armin. "Story of Eribulin Mesylate: Development of the Longest Drug Synthesis." In Topics in Heterocyclic Chemistry, 209–70. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/7081_2016_201.
Повний текст джерела"Eribulin Mesylate." In ASHP® Injectable Drug Information™, 616. ASHP, 2021. http://dx.doi.org/10.37573/9781585286850.149.
Повний текст джерелаChase, Charles, Hyeong-wook Choi, Atsushi Endo, Francis Fang, and John Orr. "Development and Commercialization of a Fully Synthetic Marine Natural Product Analogue, Halaven® (Eribulin Mesylate)." In Marine Biomedicine, 497–530. CRC Press, 2015. http://dx.doi.org/10.1201/b19081-21.
Повний текст джерелаТези доповідей конференцій з теми "Eribulin Mesylate"
Reyderman, Larisa, Timothy J. Carrothers, Borje Darpo, and Allan Kristensen. "Abstract B193: Analysis of the concentration-QTc relationship for eribulin mesylate." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 12-16, 2011; San Francisco, CA. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1535-7163.targ-11-b193.
Повний текст джерелаAlbu, Diana I., Namita Kumar, Galina Kusnetzov, Shanqin Xu, Bruce Littlefield, and Mary Woodall-Jappe. "Abstract B90: Eribulin mesylate alters immune homeostasis in mice bearing syngeneic tumors." In Abstracts: AACR Special Conference on Tumor Immunology: Multidisciplinary Science Driving Basic and Clinical Advances; December 2-5, 2012; Miami, FL. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.tumimm2012-b90.
Повний текст джерелаTanriverdi, Gamze. "Evaluation of eribulin mesylate efficacy on proliferation and apoptosis of C6 Glioblastoma cells." In 15th International Congress of Histochemistry and Cytochemistry. Istanbul: LookUs Scientific, 2017. http://dx.doi.org/10.5505/2017ichc.pp-126.
Повний текст джерелаWozniak, Krystyna, Ying Wu, Kenichi Nomoto, Bruce A. Littlefield, Christopher DesJardins, Edgar Schuck, Phil Saxton, Nancy Wong, and Barbara S. Slusher. "Abstract 4653: Pharmacokinetics and biodistribution of eribulin mesylate, paclitaxel, and ixabepilone in mouse." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-4653.
Повний текст джерелаWozniak, Krystyna, Ying Wu, Bruce A. Littlefield, Kenichi Nomoto, Christopher DesJardins, Yanke Yu, George Lai, Larisa Reyderman, and Barbara S. Slusher. "Abstract 4503: Pharmacokinetics and pharmacodynamic analysis of eribulin mesylate and paclitaxel in mouse." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-4503.
Повний текст джерелаAsano, Makoto, Kenji Hyodo, Yanke Yu, Edgar Schuck, Junji Matsui, Hiroshi Ishihara, Hiroshi Kikuchi, and Kenichi Nomoto. "Abstract 4543: Characterization of the liposomal formulation of eribulin mesylate (E7389) in mice." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-4543.
Повний текст джерелаAlbu, Diana I., Bruce A. Littlefield, and Mary Woodall-Jappe. "Abstract 1227: Macrophage depletion enhances the anticancer efficacy of eribulin mesylate in mice bearing syngeneic tumors." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-1227.
Повний текст джерелаUtsumi, T., T. Hayashi, N. Kobayashi, M. Hikichi, K. Ushimado, Y. Ri, S. Nakano, K. Fujii, and T. Ando. "Abstract P5-15-10: Eribulin mesylate (eribulin) showed inhibitory effects on epithelial-mesenchymal transition (EMT) in tumors of metastatic breast cancer patients. -First preliminary report of a prospective study-." In Abstracts: 2016 San Antonio Breast Cancer Symposium; December 6-10, 2016; San Antonio, Texas. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.sabcs16-p5-15-10.
Повний текст джерелаMeattini, Icro, Vieri Scotti, Carla De Luca Cardillo, Beatrice Detti, Vanessa Di Cataldo, and Lorenzo Livi. "Abstract P1-15-21: Safety of eribulin mesylate and concomitant palliative radiotherapy for metastatic breast cancer: A single-center experience." In Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.sabcs14-p1-15-21.
Повний текст джерелаSchwartzberg, Lee, Kristi McIntyre, Joyce O'Shaughnessy, Stefan Glück, Erhan Berrak, James Song, David Cox, and Linda Vahdat. "Abstract P5-17-02: Quality of life in patients receiving first-line eribulin mesylate for HER2- locally recurrent or MBC." In Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.sabcs14-p5-17-02.
Повний текст джерела